APA (7th ed.) Citation

Sommerhäuser, G., Kurreck, A., Stintzing, S., Heinemann, V., von Weikersthal, L. F., Dechow, T., . . . Stahler, A. (2022). Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: A prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer. BMC Cancer, 22(1), 1. https://doi.org/10.1186/s12885-022-09892-8

Chicago Style (17th ed.) Citation

Sommerhäuser, G., et al. "Study Protocol of the FIRE-8 (AIO-KRK/YMO-0519) Trial: A Prospective, Randomized, Open-label, Multicenter Phase II Trial Investigating the Efficacy of Trifluridine/tipiracil Plus Panitumumab Versus Trifluridine/tipiracil Plus Bevacizumab as First-line Treatment in Patients with Metastatic Colorectal Cancer." BMC Cancer 22, no. 1 (2022): 1. https://doi.org/10.1186/s12885-022-09892-8.

MLA (9th ed.) Citation

Sommerhäuser, G., et al. "Study Protocol of the FIRE-8 (AIO-KRK/YMO-0519) Trial: A Prospective, Randomized, Open-label, Multicenter Phase II Trial Investigating the Efficacy of Trifluridine/tipiracil Plus Panitumumab Versus Trifluridine/tipiracil Plus Bevacizumab as First-line Treatment in Patients with Metastatic Colorectal Cancer." BMC Cancer, vol. 22, no. 1, 2022, p. 1, https://doi.org/10.1186/s12885-022-09892-8.